What is the recommended management for acute respiratory distress syndrome (ARDS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 8, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Acute Respiratory Distress Syndrome (ARDS)

Core Mechanical Ventilation Strategy

All patients with ARDS must receive lung-protective ventilation with low tidal volumes of 4-8 ml/kg predicted body weight and plateau pressures maintained below 30 cm H₂O. 1

This represents the single most important intervention in ARDS management and applies universally across all severity levels (mild, moderate, and severe ARDS). 1 The evidence supporting this approach is robust, with moderate confidence in effect estimates, and this remains the cornerstone of ARDS treatment. 1

Key Ventilator Parameters:

  • Tidal volume: 4-8 ml/kg predicted body weight (strong recommendation) 1
  • Plateau pressure: ≤30 cm H₂O, ideally <28 cm H₂O 1
  • Driving pressure: Monitor and minimize (correlates with mortality) 1, 2
  • Target oxygenation: SpO₂ 92-96% or PaO₂ 70-90 mmHg 1, 2

PEEP Strategy Based on ARDS Severity

For Moderate or Severe ARDS (PaO₂/FiO₂ <200):

Use higher PEEP strategies, with the specific level tailored to oxygenation response, compliance, or plateau pressure limits. 1

This is a conditional recommendation with moderate confidence in effect estimates. 1 The optimal PEEP titration strategy remains uncertain, but options include oxygenation-based titration, titration to maximal compliance, or titration to maximal safe plateau pressure. 1

For Mild ARDS (PaO₂/FiO₂ 200-300):

Use lower PEEP strategies (typically 5-10 cm H₂O), as higher PEEP shows no benefit and may cause harm in this population. 3

Patients with mild ARDS were excluded from studies supporting higher PEEP, and there is no demonstrated benefit of high PEEP versus low PEEP in this subgroup. 3

Critical Caveat:

Monitor for deleterious responses to higher PEEP (worsened oxygenation, increased dead space, decreased compliance, or hemodynamic instability), which should prompt immediate PEEP reduction. 1

Prone Positioning

For severe ARDS (PaO₂/FiO₂ <100), implement prone positioning for more than 12 hours daily immediately. 1, 2

This is a strong recommendation with moderate confidence in effect estimates and represents a mortality-reducing intervention. 1, 2 Prone positioning should be initiated early in severe ARDS and not delayed. 2

Do NOT routinely use prone positioning for mild or moderate ARDS, as the evidence specifically supports this intervention only for severe ARDS. 1, 3

Neuromuscular Blocking Agents (NMBAs)

For early severe ARDS with ventilator dyssynchrony not mitigated by ventilator adjustments, consider cisatracurium for 24-48 hours. 1, 2

This is a conditional recommendation. 1 NMBAs may improve ventilator synchrony and potentially reduce mortality in severe ARDS. 2 Either bolus dosing or continuous infusion is appropriate. 1 Consider cessation after 48 hours or earlier for patients improving rapidly. 1

Do NOT routinely use NMBAs in mild ARDS, as the recommendation applies only to early severe ARDS. 3

Important Distinction:

When compared to deep sedation, NMBAs reduce mortality, but when compared to light sedation, there is no mortality benefit. 1 NMBAs have greater utility specifically in patients with ventilator dyssynchrony. 1

Corticosteroids

For moderate to severe ARDS (PaO₂/FiO₂ <300), administer corticosteroids early in the disease course. 1

Critical Timing Considerations:

  • Corticosteroids may be associated with increased risk of harm when initiated after 14 days of mechanical ventilation 1
  • For patients who improve rapidly, consider discontinuation at time of extubation 1
  • Monitor more closely for adverse effects in immunosuppressed patients, those with metabolic syndrome, or patients at increased risk of fungal, parasitic, or mycobacterial infections 1

The optimal corticosteroid regimen (type, dose, duration) remains uncertain. 1 For patients with corticosteroid-responsive etiologies, the regimen should be tailored to the specific condition; for others, regimens used in prior randomized controlled trials may be used. 1

Recruitment Maneuvers

For moderate or severe ARDS, recruitment maneuvers may be considered, but this is a conditional recommendation with low confidence in effect estimates. 1

Prolonged recruitment maneuvers should be avoided due to increased risk of barotrauma. 1

High-Frequency Oscillatory Ventilation (HFOV)

Do NOT routinely use high-frequency oscillatory ventilation in patients with moderate or severe ARDS. 1

This is a strong recommendation against HFOV with high confidence in effect estimates. 1

Venovenous Extracorporeal Membrane Oxygenation (VV-ECMO)

For severe ARDS with PaO₂/FiO₂ <80 or pH <7.25 with pCO₂ >60 mmHg, or early ARDS (<48 hours of mechanical ventilation) with PaO₂/FiO₂ <100, consider VV-ECMO at high-volume, dedicated centers. 1

Prerequisites Before ECMO Consideration:

Less invasive therapies must be initiated first, including: 1

  • Lung-protective ventilation
  • Prone positioning
  • Neuromuscular blockade

Important Considerations:

  • ECMO should be provided in high-volume, dedicated centers, as higher institutional case volume is associated with improved outcomes 1
  • Resource limitations should be considered, with emphasis on maximizing access for patients most likely to benefit 1
  • For patients meeting criteria at hospitals without ECMO capabilities, consider transfer to ECMO centers when feasible 1
  • Use caution in patients with prior neuromuscular conditions 1
  • Conditions associated with increased risk for futility of treatment represent contraindications 1

Uncertainty:

Long-term outcomes in ECMO survivors remain poorly understood, with some data suggesting greater decrements in health-related quality of life compared to conventional mechanical ventilation, though this is limited by small sample sizes and heterogeneity. 1

Supportive Care Measures

Infection Prevention:

  • Elevate head of bed ≥30 degrees at all times to reduce aspiration risk 2, 3
  • Provide stress ulcer prophylaxis and venous thromboembolism prophylaxis 2, 3
  • Monitor for ventilator-associated pneumonia (VAP), the leading cause of persistent fever in mechanically ventilated patients 2
  • If fever persists, perform endotracheal aspirate culture with Gram stain, assess inflammatory markers (CBC, CRP, procalcitonin), and consider nosocomial sinusitis 2

Fluid Management:

  • Implement conservative fluid management once shock is resolved to avoid worsening pulmonary edema 3

Nutritional Support:

  • Initiate early enteral nutrition with formulations containing antioxidants and anti-inflammatory amino acids, which may improve gas exchange and reduce mechanical ventilation duration 2, 3

Sedation:

  • Minimize sedation when possible to allow assessment and prevent prolonged weakness 2, 3

Monitoring:

  • Continuously assess oxygenation using PaO₂/FiO₂ ratio to detect progression between ARDS severity categories 3
  • Monitor for right ventricular dysfunction with echocardiography, particularly if sudden deterioration occurs 2, 3
  • Monitor for auto-PEEP by examining expiratory flow waveforms 3
  • Perform serial plateau pressure assessments with end-inspiratory pauses (0.3-0.5 seconds) 3

Critical Pitfalls to Avoid

  • Never delay prone positioning in severe ARDS, as it is a proven mortality-reducing intervention 2
  • Never allow tidal volumes to exceed 8 ml/kg predicted body weight, even if this requires accepting permissive hypercapnia, as ventilator-induced lung injury significantly worsens outcomes 1, 3
  • Never apply high PEEP strategies from moderate-severe ARDS protocols to mild ARDS patients, as this may cause harm without benefit 3
  • Never overlook non-pulmonary sources of fever, including sinusitis, which contributes to VAP development 2
  • Never initiate corticosteroids after 14 days of mechanical ventilation, as this is associated with increased risk of harm 1
  • Never use prolonged recruitment maneuvers due to increased barotrauma risk 1

Treatment Algorithm by ARDS Severity

Mild ARDS (PaO₂/FiO₂ 200-300):

  1. Lung-protective ventilation (4-8 ml/kg, plateau <30 cm H₂O) 1, 3
  2. Lower PEEP (5-10 cm H₂O) 3
  3. Conservative fluid management 3
  4. Standard supportive care 3

Moderate ARDS (PaO₂/FiO₂ 100-200):

  1. Lung-protective ventilation 1
  2. Higher PEEP strategy 1
  3. Consider recruitment maneuvers 1
  4. Corticosteroids 1
  5. Conservative fluid management 3

Severe ARDS (PaO₂/FiO₂ <100):

  1. Lung-protective ventilation 1
  2. Higher PEEP strategy 1
  3. Prone positioning >12 hours daily (immediately) 1, 2
  4. Consider NMBAs for 24-48 hours if ventilator dyssynchrony 1, 2
  5. Corticosteroids 1
  6. Consider recruitment maneuvers 1
  7. If PaO₂/FiO₂ <80 or pH <7.25 with pCO₂ >60: Consider VV-ECMO at high-volume center 1

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

2
Guideline

Management of Continuous Fever Spikes in Pediatric ARDS

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

3
Guideline

Management of Mild ARDS Post-Smoke Inhalation Injury

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the appropriate management plan for a patient diagnosed with Acute Respiratory Distress Syndrome (ARDS)?
What are the top causes of acute oxygen desaturation (hypoxemia)?
What test result is most supportive of a diagnosis of acute respiratory distress syndrome (ARDS) in a patient with severe hypoxemia and increased respiratory effort?
What are the differential diagnoses of Acute Respiratory Distress Syndrome (ARDS)?
What is the treatment for Acute Respiratory Distress Syndrome (ARDS)?
Can the progression of neurofibromatosis (neurofibromatosis type 1 and type 2) be reduced?
What is the appropriate twice‑daily proton‑pump inhibitor dose for an adult undergoing Helicobacter pylori eradication therapy?
What is the appropriate vitamin D (cholecalciferol) treatment regimen and dosing for a 9‑year‑old child weighing 30 kg with a 25‑hydroxy‑vitamin D level of 13.8 ng/mL (deficiency)?
In a critically ill adult receiving Cytosorb for cytokine storm or septic shock, does Cytosorb adsorb immunoglobulins and should serum immunoglobulin levels be monitored and supplemented with IVIG if they become low?
How should the ultrasound findings in a 6‑year‑old female be interpreted and managed?
What is the recommended evaluation and management for a 6‑year‑old girl with normal kidneys, a diffusely thickened bladder wall (~4 mm) and a large post‑void residual volume (~240 mL) on ultrasound?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question